EdGit schreef op 21 januari 2014 12:48:
Nog even een stukje uit een bericht van Salix 6 januari bericht van :
Then there is the Santarus pipeline. Ruconest -- the company's recombinant human C1 esterase inhibitor for hereditary angioedema, a rare but potentially fatal condition -- is an important drug to watch. Ruconest has been filed with the FDA and the efficacy, safety, and cost all compare favorably with existing drugs from ViroPharma, Shire, and CSL. Should Ruconest ultimately secure FDA approval for acute and prophylactic HAE as well as pancreatitis, there is an outside shot that this could become a blockbuster ($1 billion-plus in revenue) drug.
hier kun je het hele bericht lezen
www.dailyfinance.com/2013/11/12/salix...